{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:44:18Z","timestamp":1791243858219,"version":"4.1.0"},"reference-count":150,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,19]],"date-time":"2022-03-19T00:00:00Z","timestamp":1647648000000},"content-version":"vor","delay-in-days":383,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.cell.2021.02.030","type":"journal-article","created":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T23:37:56Z","timestamp":1616110676000},"page":"1589-1603","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":347,"title":["Novel approaches for vaccine development"],"prefix":"10.1016","volume":"184","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8520-2178","authenticated-orcid":false,"given":"Makda S.","family":"Gebre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis A.","family":"Brito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9255-5684","authenticated-orcid":false,"given":"Lisa H.","family":"Tostanoski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darin K.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Carfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan H.","family":"Barouch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cell.2021.02.030_bib1","doi-asserted-by":"crossref","first-page":"4654","DOI":"10.1128\/JVI.02696-06","article-title":"Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D","volume":"81","author":"Abbink","year":"2007","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.cell.2021.02.030_bib2","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1126\/science.aah6157","article-title":"Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys","volume":"353","author":"Abbink","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.cell.2021.02.030_bib3","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01924-17","article-title":"Rapid Cloning of Novel Rhesus Adenoviral Vaccine Vectors","volume":"92","author":"Abbink","year":"2018","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.cell.2021.02.030_bib4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cell.2021.02.030_bib5","doi-asserted-by":"crossref","first-page":"e1345","DOI":"10.1016\/S2214-109X(20)30382-X","article-title":"Certifying the interruption of wild poliovirus transmission in the WHO African region on the turbulent journey to a polio-free world","volume":"8","year":"2020","journal-title":"Lancet Glob. Health"},{"key":"10.1016\/j.cell.2021.02.030_bib6","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/mt.2010.85","article-title":"Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms","volume":"18","author":"Akinc","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.cell.2021.02.030_bib7","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1208\/s12248-009-9143-y","article-title":"Nonviral gene delivery: principle, limitations, and recent progress","volume":"11","author":"Al-Dosari","year":"2009","journal-title":"AAPS J."},{"key":"10.1016\/j.cell.2021.02.030_bib8","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa2028436","article-title":"Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults","volume":"383","author":"Anderson","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cell.2021.02.030_bib9","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/btm2.10063","article-title":"Designing biomaterials with immunomodulatory properties for tissue engineering and regenerative medicine","volume":"2","author":"Andorko","year":"2017","journal-title":"Bioeng. Transl. Med."},{"key":"10.1016\/j.cell.2021.02.030_bib10","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3390\/diseases6030074","article-title":"Herpes Simplex Virus Vectors for Gene Transfer to the Central Nervous System","volume":"6","author":"Artusi","year":"2018","journal-title":"Diseases"},{"key":"10.1016\/j.cell.2021.02.030_bib11","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cell.2021.02.030_bib12","doi-asserted-by":"crossref","first-page":"e688","DOI":"10.1016\/S2352-3018(20)30229-0","article-title":"Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1\/2a study","volume":"7","author":"Baden","year":"2020","journal-title":"Lancet HIV"},{"key":"10.1016\/j.cell.2021.02.030_bib13","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.ymthe.2017.03.035","article-title":"Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses","volume":"25","author":"Bahl","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.cell.2021.02.030_bib14","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/s41467-019-08599-y","article-title":"Diversity within the adenovirus fiber knob hypervariable loops influences primary receptor interactions","volume":"10","author":"Baker","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cell.2021.02.030_bib15","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/nrmicro3360","article-title":"Novel vaccine vectors for HIV-1","volume":"12","author":"Barouch","year":"2014","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.cell.2021.02.030_bib16","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/nm.2089","article-title":"Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys","volume":"16","author":"Barouch","year":"2010","journal-title":"Nat. Med."},{"key":"10.1016\/j.cell.2021.02.030_bib17","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1016\/j.vaccine.2011.05.025","article-title":"International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations","volume":"29","author":"Barouch","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.cell.2021.02.030_bib18","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0140-6736(18)31364-3","article-title":"Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1\/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)","volume":"392","author":"Barouch","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.cell.2021.02.030_bib19","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.immuni.2020.06.014","article-title":"Immune Sensing Mechanisms that Discriminate Self from Altered Self and Foreign Nucleic Acids","volume":"53","author":"Bartok","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.cell.2021.02.030_bib20","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1039\/C8BM01285G","article-title":"Polymeric micro- and nanoparticles for immune modulation","volume":"7","author":"Ben-Akiva","year":"2018","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.cell.2021.02.030_bib21","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.vaccine.2009.09.135","article-title":"Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers","volume":"28","author":"Bernstein","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.cell.2021.02.030_bib22","doi-asserted-by":"crossref","first-page":"4272","DOI":"10.1038\/s41467-019-12080-1","article-title":"Enhancing and shaping the immunogenicity of native-like HIV-1 envelope trimers with a two-component protein nanoparticle","volume":"10","author":"Brouwer","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cell.2021.02.030_bib23","doi-asserted-by":"crossref","first-page":"3613","DOI":"10.1038\/s41598-020-60238-5","article-title":"Characterization of a Species E Adenovirus Vector as a Zika virus vaccine","volume":"10","author":"Bullard","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cell.2021.02.030_bib24","article-title":"Heplisav-B: A Hepatitis B Vaccine With a Novel Adjuvant","author":"Champion","year":"2020","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.cell.2021.02.030_bib25","doi-asserted-by":"crossref","first-page":"10522","DOI":"10.1128\/JVI.00450-10","article-title":"Adenovirus-based vaccines: comparison of vectors from three species of adenoviridae","volume":"84","author":"Chen","year":"2010","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.cell.2021.02.030_bib26","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/iub.1625","article-title":"RNA sensors of the innate immune system and their detection of pathogens","volume":"69","author":"Chen","year":"2017","journal-title":"IUBMB Life"},{"key":"10.1016\/j.cell.2021.02.030_bib27","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jconrel.2018.01.027","article-title":"Tunable degradation of acetalated dextran microparticles enables controlled vaccine adjuvant and antigen delivery to modulate adaptive immune responses","volume":"273","author":"Chen","year":"2018","journal-title":"J.\u00a0Control. Release"},{"key":"10.1016\/j.cell.2021.02.030_bib28","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1002\/cpmo.58","article-title":"Viral Vectors for Gene Transfer","volume":"8","author":"Chen","year":"2018","journal-title":"Curr. Protoc. Mouse Biol."},{"key":"10.1016\/j.cell.2021.02.030_bib29","doi-asserted-by":"crossref","first-page":"12522","DOI":"10.1021\/acsnano.0c07197","article-title":"COVID-19 Vaccine Frontrunners and Their Nanotechnology Design","volume":"14","author":"Chung","year":"2020","journal-title":"ACS Nano"},{"key":"10.1016\/j.cell.2021.02.030_bib30","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.cell.2019.04.012","article-title":"Slow Delivery Immunization Enhances HIV Neutralizing Antibody and Germinal Center Responses via Modulation of Immunodominance","volume":"177","author":"Cirelli","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.cell.2021.02.030_bib31","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/978-1-4939-9065-8_11","article-title":"Poxviruses as Gene Therapy Vectors: Generating Poxviral Vectors Expressing Therapeutic Transgenes","volume":"1937","author":"Conrad","year":"2019","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.cell.2021.02.030_bib32","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","article-title":"SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness","volume":"586","author":"Corbett","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.cell.2021.02.030_bib33","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1056\/NEJMoa2024671","article-title":"Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates","volume":"383","author":"Corbett","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cell.2021.02.030_bib34","doi-asserted-by":"crossref","first-page":"909","DOI":"10.3389\/fimmu.2020.00909","article-title":"Factors Which Contribute to the Immunogenicity of Non-replicating Adenoviral Vectored Vaccines","volume":"11","author":"Coughlan","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cell.2021.02.030_bib35","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3390\/biomedicines7030061","article-title":"Perspective on Adenoviruses: Epidemiology, Pathogenicity, and Gene Therapy","volume":"7","author":"Crenshaw","year":"2019","journal-title":"Biomedicines"},{"key":"10.1016\/j.cell.2021.02.030_bib36","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1016\/j.vaccine.2009.03.034","article-title":"Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy","volume":"27","author":"Demento","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.cell.2021.02.030_bib37","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.it.2020.03.006","article-title":"Noncanonical Functions of Antibodies","volume":"41","author":"Dimitrov","year":"2020","journal-title":"Trends Immunol."},{"key":"10.1016\/j.cell.2021.02.030_bib38","doi-asserted-by":"crossref","first-page":"e2000025","DOI":"10.1002\/biot.202000025","article-title":"Production, Processing, and Characterization of synthetic AAV Gene Therapy Vectors","volume":"16","author":"El Andari","year":"2020","journal-title":"Biotechnol. J."},{"key":"10.1016\/j.cell.2021.02.030_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coviro.2016.06.001","article-title":"Viral vectors as vaccine carriers","volume":"21","author":"Ertl","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.cell.2021.02.030_bib40","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41541-020-0163-z","article-title":"Modified mRNA\/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection","volume":"5","author":"Espeseth","year":"2020","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.cell.2021.02.030_bib41","doi-asserted-by":"crossref","DOI":"10.1002\/wnan.1403","article-title":"Particulate delivery systems for vaccination against bioterrorism agents and emerging infectious pathogens","volume":"9","author":"Fan","year":"2017","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.cell.2021.02.030_bib42","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1016\/j.vaccine.2019.04.074","article-title":"mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials","volume":"37","author":"Feldman","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.cell.2021.02.030_bib43","volume":"Volume 6","author":"Fenner","year":"1988"},{"key":"10.1016\/j.cell.2021.02.030_bib44","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1006\/mthe.2000.0032","article-title":"Role of vector in activation of T\u00a0cell subsets in immune responses against the secreted transgene product factor IX","volume":"1","author":"Fields","year":"2000","journal-title":"Mol. Ther."},{"key":"10.1016\/j.cell.2021.02.030_bib45","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.cell.2021.02.030_bib46","article-title":"Advances in nanomaterial vaccine strategies to address infectious diseases impacting global health","author":"Fries","year":"2020","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.cell.2021.02.030_bib47","doi-asserted-by":"crossref","first-page":"e1801419","DOI":"10.1002\/adhm.201801419","article-title":"Engineering Immune Tolerance with Biomaterials","volume":"8","author":"Gammon","year":"2019","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.cell.2021.02.030_bib48","doi-asserted-by":"crossref","first-page":"14604","DOI":"10.1073\/pnas.1209367109","article-title":"Nonviral delivery of self-amplifying RNA vaccines","volume":"109","author":"Geall","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.cell.2021.02.030_bib49","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1128\/JVI.02407-10","article-title":"Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge","volume":"85","author":"Geisbert","year":"2011","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.cell.2021.02.030_bib50","article-title":"Safety and Immunogenicity of Heterologous and Homologous Two Dose Regimens of Ad26- and MVA-Vectored Ebola Vaccines: A Randomized, Controlled Phase 1 Study","author":"Goldstein","year":"2020","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.cell.2021.02.030_bib51","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0378-1119(01)00350-X","article-title":"Regulation of mRNA stability in mammalian cells","volume":"265","author":"Guhaniyogi","year":"2001","journal-title":"Gene"},{"key":"10.1016\/j.cell.2021.02.030_bib52","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.3389\/fimmu.2018.03175","article-title":"A Novel Vaccine Strategy Employing Serologically Different Chimpanzee Adenoviral Vectors for the Prevention of HIV-1 and HCV Coinfection","volume":"9","author":"Hartnell","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cell.2021.02.030_bib53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omtn.2019.01.013","article-title":"Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines","volume":"15","author":"Hassett","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.cell.2021.02.030_bib54","doi-asserted-by":"crossref","first-page":"e101591","DOI":"10.1371\/journal.pone.0101591","article-title":"Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial","volume":"9","author":"Hayton","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.cell.2021.02.030_bib55","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1182\/blood-2006-04-015024","article-title":"Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells","volume":"108","author":"Holtkamp","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.cell.2021.02.030_bib56","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1128\/JVI.01926-06","article-title":"Preferential activation of Toll-like receptor nine by CD46-utilizing adenoviruses","volume":"81","author":"Iacobelli-Martinez","year":"2007","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.cell.2021.02.030_bib57","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00159-18","article-title":"Immunogenicity and Cross-Reactivity of Rhesus Adenoviral Vectors","volume":"92","author":"Iampietro","year":"2018","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.cell.2021.02.030_bib58","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1016\/j.vaccine.2014.02.027","article-title":"Adjuvant-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release","volume":"32","author":"Ilyinskii","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.cell.2021.02.030_bib59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coi.2020.01.007","article-title":"Shaping humoral immunity to vaccines through antigen-displaying nanoparticles","volume":"65","author":"Irvine","year":"2020","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.cell.2021.02.030_bib60","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.addr.2020.06.019","article-title":"Controlling timing and location in vaccines","volume":"158","author":"Irvine","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.cell.2021.02.030_bib61","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/ni1112","article-title":"Toll-like receptor control of the adaptive immune responses","volume":"5","author":"Iwasaki","year":"2004","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.cell.2021.02.030_bib62","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA Vaccine against SARS-CoV-2 - Preliminary Report","volume":"383","author":"Jackson","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cell.2021.02.030_bib63","doi-asserted-by":"crossref","first-page":"8529","DOI":"10.1002\/anie.201203263","article-title":"Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in\u00a0vivo","volume":"51","author":"Jayaraman","year":"2012","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.cell.2021.02.030_bib64","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1089\/hum.1992.3.1-21","article-title":"Direct gene transfer into nonhuman primate myofibers in\u00a0vivo","volume":"3","author":"Jiao","year":"1992","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.cell.2021.02.030_bib65","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/j.vaccine.2018.01.029","article-title":"Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity","volume":"36","author":"John","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.cell.2021.02.030_bib66","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1097\/GRF.0b013e3182510b7b","article-title":"Prevention of maternal and congenital cytomegalovirus infection","volume":"55","author":"Johnson","year":"2012","journal-title":"Clin. Obstet. Gynecol."},{"issue":"Suppl 1","key":"10.1016\/j.cell.2021.02.030_bib67","doi-asserted-by":"crossref","first-page":"S184","DOI":"10.1002\/jgm.503","article-title":"Development and optimization of an adenovirus production process","volume":"6","author":"Kamen","year":"2004","journal-title":"J.\u00a0Gene Med."},{"key":"10.1016\/j.cell.2021.02.030_bib68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2016.05.001","article-title":"Vaccine technologies: From whole organisms to rationally designed protein assemblies","volume":"120","author":"Karch","year":"2016","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.cell.2021.02.030_bib69","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA","volume":"23","author":"Karik\u00f3","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.cell.2021.02.030_bib70","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1093\/nar\/gkr695","article-title":"Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA","volume":"39","author":"Karik\u00f3","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.cell.2021.02.030_bib71","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1146\/annurev-chembioeng-060817-084055","article-title":"Biodegradable Polymeric Nanoparticles for Therapeutic Cancer Treatments","volume":"9","author":"Karlsson","year":"2018","journal-title":"Annu. Rev. Chem. Biomol. Eng."},{"key":"10.1016\/j.cell.2021.02.030_bib72","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature09737","article-title":"Programming the magnitude and persistence of antibody responses with innate immunity","volume":"470","author":"Kasturi","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.cell.2021.02.030_bib73","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.immuni.2020.08.001","article-title":"Multifaceted Effects of Antigen Valency on B Cell Response Composition and Differentiation In\u00a0Vivo","volume":"53","author":"Kato","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.cell.2021.02.030_bib74","doi-asserted-by":"crossref","first-page":"1829829","DOI":"10.1080\/16549716.2020.1829829","article-title":"Implementation of accelerated research: strategies for implementation as applied in a phase 1 Ad26.ZEBOV, MVA-BN-Filo two-dose Ebola vaccine clinical trial in Uganda","volume":"13","author":"Kitonsa","year":"2020","journal-title":"Glob. Health Action"},{"key":"10.1016\/j.cell.2021.02.030_bib75","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jconrel.2018.04.041","article-title":"Dual TLR agonist nanodiscs as a strong adjuvant system for vaccines and immunotherapy","volume":"282","author":"Kuai","year":"2018","journal-title":"J.\u00a0Control. Release"},{"key":"10.1016\/j.cell.2021.02.030_bib76","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.chom.2019.10.001","article-title":"Adenovirus Vector-Based Vaccines Confer Maternal-Fetal Protection against Zika Virus Challenge in Pregnant IFN-\u03b1\u03b2R-\/- Mice","volume":"26","author":"Larocca","year":"2019","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.cell.2021.02.030_bib77","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.gendis.2017.04.001","article-title":"Adenovirus-Mediated Gene Delivery: Potential Applications for Gene and Cell-Based Therapies in the New Era of Personalized Medicine","volume":"4","author":"Lee","year":"2017","journal-title":"Genes Dis."},{"key":"10.1016\/j.cell.2021.02.030_bib78","doi-asserted-by":"crossref","first-page":"6482","DOI":"10.1073\/pnas.89.14.6482","article-title":"Adenovirus-mediated transfer of a recombinant human alpha 1-antitrypsin cDNA to human endothelial cells","volume":"89","author":"Lemarchand","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.cell.2021.02.030_bib79","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/nrm.2017.103","article-title":"Functional 5\u2032 UTR mRNA structures in eukaryotic translation regulation and how to find them","volume":"19","author":"Leppek","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.cell.2021.02.030_bib80","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1016\/j.ymthe.2017.08.006","article-title":"Efficient Targeting and Activation of Antigen-Presenting Cells In\u00a0Vivo after Modified mRNA Vaccine Administration in Rhesus Macaques","volume":"25","author":"Liang","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.cell.2021.02.030_bib81","doi-asserted-by":"crossref","first-page":"286","DOI":"10.4049\/jimmunol.1701005","article-title":"Rhesus Macaque Myeloid-Derived Suppressor Cells Demonstrate T Cell Inhibitory Functions and Are Transiently Increased after Vaccination","volume":"200","author":"Lin","year":"2018","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.cell.2021.02.030_bib82","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.molmed.2019.10.002","article-title":"Tailoring mRNA Vaccine to Balance Innate\/Adaptive Immune Response","volume":"26","author":"Linares-Fern\u00e1ndez","year":"2020","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.cell.2021.02.030_bib83","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.3389\/fimmu.2017.01539","article-title":"Induction of Robust B Cell Responses after Influenza mRNA Vaccination Is Accompanied by Circulating Hemagglutinin-Specific ICOS+ PD-1+ CXCR3+ T Follicular Helper Cells","volume":"8","author":"Lindgren","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cell.2021.02.030_bib84","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0065-2660(05)55002-8","article-title":"Human clinical trials of plasmid DNA vaccines","volume":"55","author":"Liu","year":"2005","journal-title":"Adv. Genet."},{"key":"10.1016\/j.cell.2021.02.030_bib85","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0140-6736(20)31866-3","article-title":"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1\/2 studies from Russia","volume":"396","author":"Logunov","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.cell.2021.02.030_bib86","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/nri.2017.106","article-title":"Beyond binding: antibody effector functions in infectious diseases","volume":"18","author":"Lu","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.cell.2021.02.030_bib87","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.3390\/v12101103","article-title":"The Old and the New: Prospects for Non-Integrating Lentiviral Vector Technology","volume":"12","author":"Luis","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.cell.2021.02.030_bib88","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41541-017-0032-6","article-title":"Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines","volume":"2","author":"Lutz","year":"2017","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.cell.2021.02.030_bib89","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1038\/nbt.3371","article-title":"In\u00a0vivo characterization of the physicochemical properties of polymer-linked TLR agonists that enhance vaccine immunogenicity","volume":"33","author":"Lynn","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.cell.2021.02.030_bib90","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.cell.2019.01.046","article-title":"Induction of Potent Neutralizing Antibody Responses by a Designed Protein Nanoparticle Vaccine for Respiratory Syncytial Virus","volume":"176","author":"Marcandalli","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.cell.2021.02.030_bib91","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.vaccine.2016.11.040","article-title":"Immunogenicity and protective efficacy induced by self-amplifying mRNA vaccines encoding bacterial antigens","volume":"35","author":"Maruggi","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.cell.2021.02.030_bib92","doi-asserted-by":"crossref","first-page":"eaau2710","DOI":"10.1126\/sciimmunol.aau2710","article-title":"Prolonged evolution of the memory B cell response induced by a replicating adenovirus-influenza H5 vaccine","volume":"4","author":"Matsuda","year":"2019","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.cell.2021.02.030_bib93","doi-asserted-by":"crossref","first-page":"24075","DOI":"10.1073\/pnas.1908052116","article-title":"mRNA structure regulates protein expression through changes in functional half-life","volume":"116","author":"Mauger","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.cell.2021.02.030_bib94","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/0042-6822(88)90302-9","article-title":"A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5","volume":"163","author":"McGrory","year":"1988","journal-title":"Virology"},{"key":"10.1016\/j.cell.2021.02.030_bib95","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1080\/14760584.2019.1588113","article-title":"A review of 65 years of human adenovirus seroprevalence","volume":"18","author":"Mennechet","year":"2019","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.cell.2021.02.030_bib96","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-020-2607-z","article-title":"Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques","volume":"586","author":"Mercado","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.cell.2021.02.030_bib97","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41586-020-2639-4","article-title":"Phase I\/II study of COVID-19 RNA vaccine BNT162b1 in adults","volume":"586","author":"Mulligan","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.cell.2021.02.030_bib98","doi-asserted-by":"crossref","first-page":"eaaz6893","DOI":"10.1126\/sciadv.aaz6893","article-title":"Impact of mRNA chemistry and manufacturing process on innate immune activation","volume":"6","author":"Nelson","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.cell.2021.02.030_bib99","doi-asserted-by":"crossref","first-page":"3926","DOI":"10.1021\/nn3057005","article-title":"Gold nanoparticles as a vaccine platform: influence of size and shape on immunological responses in\u00a0vitro and in\u00a0vivo","volume":"7","author":"Niikura","year":"2013","journal-title":"ACS Nano"},{"key":"10.1016\/j.cell.2021.02.030_bib100","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.addr.2015.10.020","article-title":"Combining antigen and immunomodulators: Emerging trends in antigen-specific immunotherapy for autoimmunity","volume":"98","author":"Northrup","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.cell.2021.02.030_bib101","doi-asserted-by":"crossref","first-page":"4031","DOI":"10.1073\/pnas.1704507114","article-title":"Simply put: Vaccination saves lives","volume":"114","author":"Orenstein","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.cell.2021.02.030_bib102","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.ymthe.2018.12.011","article-title":"Improving mRNA-Based Therapeutic Gene Delivery by Expression-Augmenting 3\u2032 UTRs Identified by Cellular Library Screening","volume":"27","author":"Orlandini von Niessen","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.cell.2021.02.030_bib103","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1377\/hlthaff.2015.1086","article-title":"Return On Investment From Childhood Immunization In Low- And Middle-Income Countries, 2011-20","volume":"35","author":"Ozawa","year":"2016","journal-title":"Health Aff. (Millwood)"},{"key":"10.1016\/j.cell.2021.02.030_bib104","doi-asserted-by":"crossref","first-page":"e809","DOI":"10.1016\/S2352-3018(19)30230-9","article-title":"The global burden of HIV and prospects for control","volume":"6","author":"Pandey","year":"2019","journal-title":"Lancet HIV"},{"key":"10.1016\/j.cell.2021.02.030_bib105","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1007\/s00705-015-2575-z","article-title":"Taxonomy proposal for Old World monkey adenoviruses: characterisation of several non-human, non-ape primate adenovirus lineages","volume":"160","author":"Pant\u00f3","year":"2015","journal-title":"Arch. Virol."},{"key":"10.1016\/j.cell.2021.02.030_bib106","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1016\/j.actbio.2012.06.006","article-title":"Differential functional effects of biomaterials on dendritic cell maturation","volume":"8","author":"Park","year":"2012","journal-title":"Acta Biomater."},{"key":"10.1016\/j.cell.2021.02.030_bib107","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.nano.2018.10.001","article-title":"Overcoming challenges in treating autoimmuntity: Development of tolerogenic immune-modifying nanoparticles","volume":"18","author":"Pearson","year":"2019","journal-title":"Nanomedicine (Lond.)"},{"key":"10.1016\/j.cell.2021.02.030_bib108","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cell.2021.02.030_bib109","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/mt.2012.202","article-title":"Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines","volume":"21","author":"Pollard","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.cell.2021.02.030_bib110","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/sj.gt.3302964","article-title":"Spontaneous cellular uptake of exogenous messenger RNA in\u00a0vivo is nucleic acid-specific, saturable and ion dependent","volume":"14","author":"Probst","year":"2007","journal-title":"Gene Ther."},{"key":"10.1016\/j.cell.2021.02.030_bib111","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.virol.2011.02.003","article-title":"Innate immune sensing of DNA viruses","volume":"411","author":"Rathinam","year":"2011","journal-title":"Virology"},{"key":"10.1016\/j.cell.2021.02.030_bib112","article-title":"mRNA based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus neutralizing antibodies and mediates protection in rodents","author":"Rauch","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.cell.2021.02.030_bib113","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nature04721","article-title":"Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity","volume":"441","author":"Roberts","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.cell.2021.02.030_bib114","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1001\/jama.2020.20449","article-title":"Association of Use of a Meningococcus Group B Vaccine With Group B Invasive Meningococcal Disease Among Children in Portugal","volume":"324","author":"Rodrigues","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.cell.2021.02.030_bib115","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0092-8674(92)90213-V","article-title":"In\u00a0vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium","volume":"68","author":"Rosenfeld","year":"1992","journal-title":"Cell"},{"key":"10.1016\/j.cell.2021.02.030_bib116","article-title":"Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1\/2a, double-blind, randomized, placebo-controlled trial","author":"Sadoff","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.cell.2021.02.030_bib117","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2034201","article-title":"Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine","author":"Sadoff","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cell.2021.02.030_bib118","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nrd4278","article-title":"mRNA-based therapeutics--developing a new class of drugs","volume":"13","author":"Sahin","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.cell.2021.02.030_bib119","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/nm.4322","article-title":"A live-attenuated Zika virus vaccine candidate induces sterilizing immunity in mouse models","volume":"23","author":"Shan","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.cell.2021.02.030_bib120","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1073\/pnas.0804897106","article-title":"Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome","volume":"106","author":"Sharp","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.cell.2021.02.030_bib121","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.ymthe.2020.01.001","article-title":"Immune Responses to Viral Gene Therapy Vectors","volume":"28","author":"Shirley","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.cell.2021.02.030_bib122","doi-asserted-by":"crossref","first-page":"11960","DOI":"10.1016\/S0021-9258(19)38494-7","article-title":"Catalytic activity of vaccinia mRNA capping enzyme subunits coexpressed in Escherichia coli","volume":"265","author":"Shuman","year":"1990","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.cell.2021.02.030_bib123","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3344\/kjp.2020.33.3.201","article-title":"Recombinant zoster vaccine (Shingrix\u00ae): a new option for the prevention of herpes zoster and postherpetic neuralgia","volume":"33","author":"Singh","year":"2020","journal-title":"Korean J. Pain"},{"key":"10.1016\/j.cell.2021.02.030_bib124","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1111\/jam.14478","article-title":"Recent updates on drug resistance in Mycobacterium tuberculosis","volume":"128","author":"Singh","year":"2020","journal-title":"J.\u00a0Appl. Microbiol."},{"key":"10.1016\/j.cell.2021.02.030_bib125","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.coi.2016.05.011","article-title":"New concepts in HIV-1 vaccine development","volume":"41","author":"Stephenson","year":"2016","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.cell.2021.02.030_bib126","doi-asserted-by":"crossref","first-page":"e410","DOI":"10.1016\/S2352-3018(20)30001-1","article-title":"Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010\/HPX1002) and a preclinical study in rhesus monkeys (NHP 17-22)","volume":"7","author":"Stephenson","year":"2020","journal-title":"Lancet HIV"},{"key":"10.1016\/j.cell.2021.02.030_bib127","doi-asserted-by":"crossref","first-page":"7179","DOI":"10.4049\/jimmunol.174.11.7179","article-title":"Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein","volume":"174","author":"Sumida","year":"2005","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.cell.2021.02.030_bib128","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1016\/j.vaccine.2015.03.063","article-title":"M2e-immobilized gold nanoparticles as influenza A vaccine: Role of soluble M2e and longevity of protection","volume":"33","author":"Tao","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.cell.2021.02.030_bib129","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S1473-3099(20)30016-5","article-title":"Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in adults in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial","volume":"20","author":"Tapia","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.cell.2021.02.030_bib130","doi-asserted-by":"crossref","first-page":"e120692","DOI":"10.1172\/jci.insight.120692","article-title":"TLR-adjuvanted nanoparticle vaccines differentially influence the quality and longevity of responses to malaria antigen Pfs25","volume":"3","author":"Thompson","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.cell.2021.02.030_bib131","doi-asserted-by":"crossref","first-page":"e0208328","DOI":"10.1371\/journal.pone.0208328","article-title":"First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17\u00a0months old infants and children","volume":"13","author":"Tiono","year":"2018","journal-title":"PLoS ONE"},{"key":"10.1016\/j.cell.2021.02.030_bib132","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.addr.2017.03.005","article-title":"Engineering self-assembled materials to study and direct immune function","volume":"114","author":"Tostanoski","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.cell.2021.02.030_bib133","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1126\/science.8456302","article-title":"Heterologous protection against influenza by injection of DNA encoding a viral protein","volume":"259","author":"Ulmer","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.cell.2021.02.030_bib134","series-title":"Adenoviruses","author":"Usman","year":"2020"},{"key":"10.1016\/j.cell.2021.02.030_bib135","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s41586-020-2608-y","article-title":"ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques","volume":"586","author":"van Doremalen","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.cell.2021.02.030_bib136","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1634\/theoncologist.7-1-46","article-title":"Adenoviral gene therapy","volume":"7","author":"Vorburger","year":"2002","journal-title":"Oncologist"},{"key":"10.1016\/j.cell.2021.02.030_bib137","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.cell.2021.02.030_bib138","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1016\/j.vaccine.2016.03.069","article-title":"Adenovirus type 35-vectored tuberculosis vaccine has an acceptable safety and tolerability profile in healthy, BCG-vaccinated, QuantiFERON(\u00ae)-TB Gold (+) Kenyan adults without evidence of tuberculosis","volume":"34","author":"Walsh","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.cell.2021.02.030_bib139","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/s41563-018-0147-9","article-title":"Biomaterial-assisted targeted modulation of immune cells in cancer treatment","volume":"17","author":"Wang","year":"2018","journal-title":"Nat. Mater."},{"key":"10.1016\/j.cell.2021.02.030_bib140","series-title":"Immunization","year":"2019"},{"key":"10.1016\/j.cell.2021.02.030_bib141","first-page":"29","article-title":"Immune evasion by adenovirus E3 proteins: exploitation of intracellular trafficking pathways","volume":"273","author":"Windheim","year":"2004","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.cell.2021.02.030_bib142","first-page":"3","article-title":"The mechanism of naked DNA uptake and expression","volume":"54","author":"Wolff","year":"2005","journal-title":"Adv. Genet."},{"key":"10.1016\/j.cell.2021.02.030_bib143","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1126\/science.1690918","article-title":"Direct gene transfer into mouse muscle in\u00a0vivo","volume":"247","author":"Wolff","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.cell.2021.02.030_bib144","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.3201\/eid1210.060078","article-title":"Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa","volume":"12","author":"Xiang","year":"2006","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.cell.2021.02.030_bib145","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1021\/acsbiomaterials.9b01255","article-title":"Integrating Biomaterials and Immunology to Improve Vaccines Against Infectious Diseases","volume":"6","author":"Yenkoidiok-Douti","year":"2020","journal-title":"ACS Biomater. Sci. Eng."},{"key":"10.1016\/j.cell.2021.02.030_bib146","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/jcb.22328","article-title":"The influence of innate and pre-existing immunity on adenovirus therapy","volume":"108","author":"Zaiss","year":"2009","journal-title":"J.\u00a0Cell. Biochem."},{"key":"10.1016\/j.cell.2021.02.030_bib147","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.immuni.2016.09.011","article-title":"Structural Analysis Reveals that Toll-like Receptor 7 Is a Dual Receptor for Guanosine and Single-Stranded RNA","volume":"45","author":"Zhang","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.cell.2021.02.030_bib148","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.ymthe.2006.03.027","article-title":"A chimpanzee-origin adenovirus vector expressing the rabies virus glycoprotein as an oral vaccine against inhalation infection with rabies virus","volume":"14","author":"Zhou","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.cell.2021.02.030_bib149","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","article-title":"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"396","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.cell.2021.02.030_bib150","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet"}],"container-title":["Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0092867421002191?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0092867421002191?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T11:54:17Z","timestamp":1758801257000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0092867421002191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":150,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S0092867421002191"],"URL":"https:\/\/doi.org\/10.1016\/j.cell.2021.02.030","relation":{},"ISSN":["0092-8674"],"issn-type":[{"value":"0092-8674","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel approaches for vaccine development","name":"articletitle","label":"Article Title"},{"value":"Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cell.2021.02.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}